Business
Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for this year.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
Gilead Sciences and Second Genome forged a four-year strategic collaboration that will boost chances to discover and develop new targets and drug candidates for the treatment of inflammatory bowel disease through microbiome research.
Disgraced pharma executive Martin Shkreli is pleading to be temporarily let out of prison in order to join in the fight against COVID-19, the disease that has swept across the globe infecting more than 1.3 million people across the globe.
After nearly five years at Alkermes, Lisa von Moltke has left the company and taken a new position as chief medical officer of Seres Therapeutics.
Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
Takeda Pharmaceutical and a subsidiary of Germany-based Evotec SE forged a long-term research collaboration that will support the Japanese company’s growing number of research stage gene therapy discovery programs.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
Keele, UK, 31 March 2020: Cobra Biologics, an international CDMO for biologics and pharmaceuticals, announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19, for fast-tracked clinical trials for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.